roxatidine acetate (roxatidine)

12/01/1995 - "Roxatidine acetate is a novel H2-receptor antagonist and several studies have shown that it is effective in healing duodenal ulcers. "
09/01/1999 - "In conclusions, roxatidine is effective in the healing of duodenal ulcer. "
01/01/1988 - "The results confirm that roxatidine acetate is a safe and effective treatment for duodenal ulcer disease."
01/01/1988 - "Thus, maintenance treatment with roxatidine acetate 75 mg daily proved a safe and effective method of preventing symptomatic duodenal ulcer relapse."
08/01/1995 - "Double-blind, randomized trial of roxatidine 150 mg in the early evening versus bedtime administration in the short-term treatment of duodenal ulcer."

01/01/1988 - "Roxatidine acetate in the long term maintenance of gastric ulcers."
01/01/1988 - "In 363 outpatients with endoscopically confirmed gastric ulcers the efficacy and safety of roxatidine acetate 150 mg at night was compared to 75 mg twice daily. "
01/01/1988 - "A comparison of roxatidine acetate 150 mg once daily and 75 mg twice daily in gastric ulcer healing."
01/01/1991 - "The total ulcer recurrence rate was significantly lower in patients on active treatment: 35% and 32% of patients with a previously healed duodenal or gastric ulcer relapsed within 12 months while on roxatidine acetate, compared with 66% and 71% of patients in each study on placebo (life-table analysis, P = 0.0001). "
01/01/1988 - "The present study suggests that 8 weeks of treatment with roxatidine acetate 75 mg twice a day produces effective and safe acute management of gastric ulcers which is comparable to that seen with ranitidine."

01/01/1998 - "Effects of changing the type of H2-blocker in the treatment of H2-blocker-resistant ulcers: comparison of roxatidine acetate hydrochloride and other H2-blockers."
08/01/1997 - "Roxatidine (25, 70, 100 and 140 mg kg-1) dose-dependently reduces ulcer size and number by 24.6, 55.6, 85.3 and 89.0% and by (+7.2), 14.3, 57.1 and 67.9%, respectively. "
10/01/1996 - "On the other hand, roxatidine did not prevent the ulcer formation at the same dose level of antisecretory activity. "
07/01/1992 - "Ulcer healing (endoscopically determined) with roxatidine was more effective than placebo at both wk 0-2 (R = 33.9%, P = 21.9%, p = 0.018) and wk 2-4 (R = 68.2%, P = 29.7%, p less than 0.001), with an overall 4-wk effectiveness of 78.9% compared to 44.8% (p less than 0.001). "
01/01/1988 - "After 14 days' treatment with roxatidine acetate substantial reductions in ulcer sizes had been obtained, in addition to healing rates of 87 to 89%, with no significant differences between the dosage regimens. "

01/01/1991 - "It is concluded that 75 mg of roxatidine acetate at night is a safe and effective maintenance treatment to sustain remission in patients with peptic ulcers."
01/01/1988 - "Clinical studies on the use of roxatidine acetate for the treatment of peptic ulcer in Japan."
08/01/2010 - "Roxatidine is an H(2) receptor blocker frequently used in the treatment of peptic ulcers. "
01/01/1991 - "The efficacy and safety of 75 mg of roxatidine acetate at night as maintenance treatment for chronic peptic ulcer disease was investigated in two double-blind randomized placebo-controlled multicenter studies. "
01/01/1991 - "Roxatidine acetate as maintenance treatment for patients with peptic ulcer disease. "

01/01/1989 - "These studies show that roxatidine acetate is comparable to other potent H2-receptor antagonists in terms of cumulative healing rates, pain relief, and safety. "
01/01/1988 - "The present data suggests that a single bedtime dose of roxatidine acetate 150 mg produces effective duodenal ulcer healing and pain relief equivalent to that produced by a twice daily dosage regimen."
07/01/1995 - "Thus roxatidine achieves the primary therapeutic goal of relief of pain better than ranitidine."
08/01/1993 - "At the end of 4 weeks, total pain relief was obtained in 74% and 70% patients receiving Roxatidine and Cimetidine respectively. "
12/01/1995 - "Both drugs relieved pain rapidly, usually within a week, and at repeat endoscopy at 4 weeks most ulcers (78%) were healed, 77.0 and 79.5 per cent in ranitidine and roxatidine, and in those patients in whom healing was not completed the healing rate had risen appreciably to 89.8 and 93.8 per cent respectively at 6 weeks. "